Page 1 of 51 
1 TITLE PAGE  
 
VERTEX PHARMACEUTICALS INCORPORATED  
Clinical Study Protocol  
A Phase 2B Randomized, Double -blind, 
Placebo -controlled, Dose -ranging, Parallel -design 
Study of the Efficacy and Safety of VX -150 for Acute 
Pain Following Bunionectomy  
Vertex Study Number: VX18 ‑150‑104 
 
Date of Protocol:  26 September 2018 (Version  2.0). 
Vertex Pharmaceuticals Incorporated  
[ADDRESS_1237016] be informed that the information is confidential and 
may not be further disclosed by [CONTACT_476].  

Protocol VX18 -150-104, Version  2.0 Page 3 of 51 
Vertex Pharmaceuticals Incorporated   2 PROTOCOL SYNOPSIS  
Title  A Phase 2B Randomized, Double -blind, Placebo -controlled, Dose -ranging, Parallel -
design Study of the Efficacy and Safety of VX -150 for Acute Pain Following 
Bunionectomy  
  
Brief Title  A Dose -ranging Study to Evaluate Efficacy and Safety of VX -150 in Subjects With 
Acute Pain Following Bunionectomy  
  
Clinical Phase and 
Clinical Study Type  Phase  2B efficacy and safety  
  
Objectives  Primary Objective  
To evaluate the dose- response relationship of VX -150 in treating acute pain following 
bunionectomy  
Secondary Objectives  
• To evaluate the safety and tolerability of VX -150 
• To evaluate the pharmacokinetics (PK) of VRT -1207355 and the metabolite 
VRT -1268114 (M5)  
  
Endpoints  Primary Endpoint  
Time -weighted sum of the pain intensity difference between VX- 150 versus placebo 
as recorded on a Numeric Pain Rating Scale (NPRS) 0 to 24 hours (SPID 24) after 
the first dose  
Secondary Endpoints  
• Time -weighted sum of the pain  intensity difference between VX -150 versus 
placebo as recorded on an NPRS 0 to 48 hours (SPID 48) after the first dose  
• Proportions of subjects with at least 30%, 50%, or 70% reduction in NPRS at [ADDRESS_1237017] dose of VX -150 versus placebo 
• Time to onset of “confirmed perceptible pain relief” and “meaningful pain relief” 
after the first dose of VX -150 versus placebo 
• Plasma PK parameters of VRT -1207355 and the metabolite M5 
• Safety and tolerability based on the incidence and type of adverse events ( AEs), 
changes from baseline in clinically significant laboratory test results, and vital 
signs at designated visits  
Number of Subjects  Approximately 242 subjects.  
  
Study Population  Male and female subjects who are between the ages of 18  and 65  years (inclusive) 
with pain that is ≥4 on the NPRS and is moderate or severe on the Verbal Categorical Rating Scale (VRS) after bunionectomy  
  

Protocol VX18 -150-104, Version  2.0 Page 4 of 51 
Vertex Pharmaceuticals Incorporated   Investigational Drug  Active substance: VX -150 
 Activity: Voltage -gated sodiu m channel  (Na v) 1.8 inhibitor  
 Strength and route of administration: 250-mg capsules administered orally  
 
Study Duration  Excluding the Screening Period, each subject will participate in the study for 11  (± 2) 
days (from Day  -1 to the Safety Follow -up Phone Interview).  
  
Study Design  This is a Phase 2B randomized, double -blind, placebo -controlled, dose -ranging, 
6-arm, parallel -design study. Subjects will receive a primary unilateral first metatarsal 
bunionectomy repair on Day -1. A continuous popliteal sciatic block infusion (0.2% 
ropi[INVESTIGATOR_10319]) will be started after surgery and  will be removed between 3AM and 
5AM on Day 1. After removal of the popliteal sciatic block, a subject can be 
randomized once the subject requests the first dose of study drug for  pain relief, and 
the subject’s pain is ≥[ADDRESS_1237018] udy. 
A total of approximately 242 subjects will be randomized 2:2:2: 2:1:2 to 6 treatment 
arms , evaluating a range of  5 VX-150 dose levels  as shown in Table  2-1: 
Table 2-1 VX-150 Doses by [CONTACT_884245]-150 1 (highest)  First dose [ADDRESS_1237019] dose 500 mg, then 250 mg 
q12h  44 
 5 (lowest)  250 mg qd  22 
Placebo    44 
q12h: every 12 hours; qd: daily  
Note: q12h dosing will be th rough [ADDRESS_1237020] dose of study drug to receive rescue medication, and subjects should generally not receive rescue medication unless their 
NPRS is ≥4. However, subjects may receive rescue medication at any time after the 
first dose of study drug per their request. The rescue medication will be ibuprofen 
(400 mg [oral]  every 4 hours  [q4h] as needed [prn] ). 
  
Assessments  Efficacy : 11-point NPRS, 4 -point VRS, double -stopwatch assessment,  
 
Safety: AEs, clinical laboratory assessments, clinical evaluation of vital signs, ECGs, and physical examinations.  
PK: Plasma PK parameters of VRT -1207355 and the metabolite M5 
 

Protocol VX18 -150-104, Version  2.0 Page 5 of 51 
Vertex Pharmaceuticals Incorporated    
  
Statistical Analyses  The primary efficacy endpoint is the time -weighted sum of the pain intensity 
difference between VX -150 versus placebo as recorded on a NPRS 0 to 24 hours 
(SPID 24) after the first dose.  
The primary efficacy analysis will be using the MCP -Mod (multiple comparison 
procedures with modeling techniques) approach to detect the dose- response 
relationship from a candidate set of 4 dose -response models (Linear, Emax, Logistic , 
and Sigmoid Emax). Two -sided P value for each dose- response model will be 
provided.  
Both MCP -Mod approach  in SPID 24 between VX -150 and 
placebo will be based on an analysis of covariance (ANCOVA) model. The model 
will include the time -weighted sum of t he pain intensity difference 0 to 24 hours 
(SPID 24) after the first dose as the dependent variable, and treatment as a fixed 
effect, with adjustment for stratification factors, i.e., site and sex, and baseline pain as 
a covariate.  
  

Protocol VX18 -150-104, Version  2.0 Page 6 of 51 
Vertex Pharmaceuticals Incorporated   3 SCHEDULE OF ASSESSMENTS  
Schedules of assessments are in  Table 3-1 and  Table 3-2. 
Table 3-1 Study VX18 -150- 104: Screening Period Prior to Surgery  
Assessment  Screening Period Prior to Surgery  
Day -28 to Day  -2 
Outpatient visit  X 
Informed consent form  X 
Inclusion/exclusion criteria  X 
Demographics  X 
Medical history  X 
History of drug and alcohol use  X 
Weight, height, and BMIa X 
Vital signsb X 
Standard 12 -lead ECGc X 
Physical examination  X 
Serum FSH (postmenopausal female subjects 
only)   X 
Serum β -hCG (all female subjects)d X 
Serology (HBsAg, HCV, and HIV  1/HIV  2)e X 
Serum chemistryf X 
Hematologyf X 
Coagulationf X 
Urinalysis  X 
Drug test (urine)  X 
Prior use of opi[INVESTIGATOR_884233] X 
Medications reviewh Continuous from signing of ICF through Safety Follow -up 
Treatments and procedures review  Continuous from signing of ICF through Safety Follow -up 
Adverse events  Continuous from signing of ICF through Safety Follow -up 
β-hCG : beta-human chorionic gonadotropin; BMI:  body mass index; FSH:  follicle -stimulating hormone;  
HBsAg:  hepatitis B surface antigen; HCV: hepatitis C virus; HIV -1 and HIV -2 Abs:  antibodies against human 
immunodeficiency viruses 1 and 2; ICF:  informed consent form   a Weight and height will be measured with shoes  off. 
b Vital signs (pulse rate, respi[INVESTIGATOR_1487], blood pressure, and temperature) will be assessed in the supi[INVESTIGATOR_884234] [ADDRESS_1237021] be conducted within 7 days before Day  1.  
e Serology includes testing for HBsAg and antibodies to HCV and human immunodeficiency viruses 1 and 2 (HIV  1/HIV  2). 
f Blood samples will be collected for clinical laboratory assessments following a fast of at least 4 hours.  
g Any opi[INVESTIGATOR_660312] 12 months of Screening Visit will be recorded.  
h All medications taken within 14 days before screening through the end of the study will be recorded.  

Protocol VX18 -150-104, Version  2.0 Page 7 of 51 
Vertex Pharmaceuticals Incorporated   Table 3-2 Study VX18 -150-104: Day -1, Treatment Period and Safety Follow- up 
Event/Assessment  Day -1 Day 1 Day 2 Day 3 Safety Follow -up  
7 (± 2) Days After Last 
Dose of Study Drug  
Admission to CRU  X     
Bunionectomy  X     
Randomization   X    
Study drug dosinga  X X X  
Discharge from CRUb    X  
Phone interviewc     X 
Vital signsd X X X X  
Standard 12 -lead ECG   Xe    
Physical examination  X     
β-hCG (urine)  Xf     
Serum chemistry  Xg     
Hematology  X     
Coagulation  X     
PK blood sampleh  X X X   a To maintain the blind , all subjects will receive the same number of capsules. 
b Subjects will be discharged on Day  [ADDRESS_1237022] dose of the day. Vital signs (pulse rate, respi[INVESTIGATOR_1487], blood pressure, and temperature) will be 
assessed in the supi[INVESTIGATOR_884235] [ADDRESS_1237023] dose, and at 4 ( ± 1) hours after the first dose on Day 1. ECGs will be done in the supi[INVESTIGATOR_884236], such as blood draws. Subjects will rest for at least [ADDRESS_1237024] completed the screening assessments, clinical chemistry, hematology, and coagulation do not need to be 
performed at Day  -1.  
h PK blood samples will be collected at 0  hour (before dosing) and at 1, 2, 4, 6, 8, and [ADDRESS_1237025].  

Protocol VX18 -150-104, Version  2.0 Page 8 of 51 
Vertex Pharmaceuticals Incorporated   Table 3-2 Study VX18 -150-104: Day -1, Treatment Period and Safety Follow- up 
Event/Assessment  Day -1 Day 1 Day 2 Day 3 Safety Follow -up  
7 (± 2) Days After Last 
Dose of Study Drug  
Drug test (urine)  X     
Alcohol test (breath)  X     
NPRSj  X X X  
VRSk  X    
Double -stopwatch assessment   X    
Medications review  Continuous from signing of ICF through Safety Follow -up 
Treatments and procedures review  Continuous from signing of ICF through Safety Follow -up 
Adverse events  Continuous from signing of ICF through Safety Follow -up 
β-hCG : beta-human chorionic gonadotropin; CRU: clinical research unit; NPRS: Numeric Pain Rating Scale; PK: pharmacokinetic; VRS: Verbal Categorical 
Rating Scale  
 
 Starting on Day 1, subjects will report their pain on the NPRS at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36,  40, 44, and 48 hours (± 5 minutes) after 
the first dose of study drug. In addition, pain intensity on the NPRS will be recorded when the subject requests the first do se of study drug for pain relief and 
immediately before each administration of rescue med ication . 
k On Day 1, subjects will report their pain on the VRS when they request the first dose of study drug for pain relief.  

Protocol VX1 8-150-104, Version  2.[ADDRESS_1237026] of Abbreviations................................................................................................................ 13  
5 Introduction.......................................................................................................................... 15  
5.1 Background ..................................................................................................................... 15  
5.2 Study Rationale  .............................................................................................................. 15  
6 Study Objectives  .................................................................................................................. 15  
6.1 Primary Objective  ........................................................................................................... 15  
6.2 Secondary Objectives  ..................................................................................................... 16  
7 Study Endpoints  ................................................................................................................... 16  
7.1 Primary Endpoint ............................................................................................................ 16  
7.2 Secondary Endpoints ...................................................................................................... 16  
8 Study Population .................................................................................................................. 16  
8.1 Inclusion Criteria  ............................................................................................................ 16  
8.2 Exclusion Criteria  ........................................................................................................... 17  
9 Study Implementation  ......................................................................................................... 18  
9.1 Study Design  .................................................................................................................. 18  
9.1.1  Screening  ................................................................................................................ 19  
[IP_ADDRESS]  Repetition of Screening Assessments  .............................................................. 19  
[IP_ADDRESS]  Rescreening  ...................................................................................................... [ADDRESS_1237027] and Disease Characteristics  ............................................................................... 28  
11.2  Pharmacokinetics  ............................................................................................................ 28  
11.2.1  Blood Sampling ...................................................................................................... 28  
11.2.2  Processing and Handling of Pharmacokinetic Samples ......................................... 29  
11.2.3  Bioanalysis .............................................................................................................. 29  
11.4  Efficacy  ........................................................................................................................... 29  
11.5  Safety  .............................................................................................................................. 30  
11.5.1  Adverse Events  ....................................................................................................... 30  
11.5.2  Clinical Laboratory Assessments  ........................................................................... 30  
11.5.3  Physical Examinations and Vital Signs  .................................................................. 32  
11.5.4  Electrocardiograms  ................................................................................................. 32  
11.5.5  Contraception and Pregnancy ................................................................................. 33  
[IP_ADDRESS]  Contraception ................................................................................................... 33  
[IP_ADDRESS]  Pregnancy  ......................................................................................................... 34  
12 Statistical and Analytical Plans .......................................................................................... 34  
12.1  Sample Size and Power  .................................................................................................. 34  
12.2  Analysis Sets  .................................................................................................................. 35  
12.3  Statistical Analysis  ......................................................................................................... 35  
12.3.1  General Considerations ........................................................................................... 35  
12.3.2  Background Characteristics  .................................................................................... 36  
[IP_ADDRESS]  Subject Disposition  .......................................................................................... 36  
[IP_ADDRESS]  Demographics and Baseline Characteristics  .................................................... 36  
[IP_ADDRESS]  Prior and Concomitant Medications................................................................. 36  
[IP_ADDRESS]  Study Drug Exposure and Compliance ............................................................ 36  
12.3.3  Efficacy Analysis  .................................................................................................... 36  
[IP_ADDRESS]  Analysis of Primary Variable  ........................................................................... 36  
[IP_ADDRESS]  Analysis of Secondary Efficacy Variables  ....................................................... 37  
12.3.4  Safety Analysis  ....................................................................................................... 38  
[IP_ADDRESS]  Adverse Events ................................................................................................. 38  
[IP_ADDRESS]  Clinical Laboratory Assessments  ..................................................................... 38  
[IP_ADDRESS]  Electrocardiogram  ............................................................................................ 38  
[IP_ADDRESS]  Vital Signs  ........................................................................................................ 39  
[IP_ADDRESS]  Physical Examination  ....................................................................................... 39  
[IP_ADDRESS]  Other Safety Analysis  ...................................................................................... 39  
12.3.5  Other Analysis  ........................................................................................................ 39  

Protocol VX1 8-150-104, Version  2.0 Page 11 of 51 
Vertex Pharmaceuticals Incorporated   12.3.6  Interim and Independent Data Monitoring Committee Analyses ........................... 39  
12.4  Clinical Pharmacology Analysis  .................................................................................... 39  
12.4.1  Pharmacokinetic Analysis  ...................................................................................... 39  
12.4.2  Pharmacokinetic/Pharmacodynamic Analyses  ....................................................... 39  
13 Procedural, Ethical, Regulatory, and Administrative Considerations ........................... 40  
13.1  Adverse Event and Serious Adverse Event Documentation, Severity Grading, and 
Reporting ........................................................................................................................ 40  
13.1.1  Adverse Events  ....................................................................................................... 40  
[IP_ADDRESS]  Definition of an Adverse Event........................................................................ 40  
[IP_ADDRESS]  Clinically Significant Assessments  .................................................................. 40  
[IP_ADDRESS]  Documentation of Adverse Events................................................................... 40  
[IP_ADDRESS]  Adverse Event Severity  .................................................................................... 41  
[IP_ADDRESS]  Adverse Event  Causality  .................................................................................. 41  
[IP_ADDRESS]  Study Drug Action Taken ................................................................................ 42  
[IP_ADDRESS]  Adverse Event Outcome .................................................................................. 42  
[IP_ADDRESS]  Treatment Given ............................................................................................... 43  
13.1.2  Serious Adverse Events .......................................................................................... 43  
[IP_ADDRESS]  Definition of a Serious Adverse Event............................................................. 43  
[IP_ADDRESS]  Reporting and Documentation of Serious Adverse Events .............................. 44  
[IP_ADDRESS]  Expedited Reporting and Investigator Safety Letters  ...................................... [ADDRESS_1237028] of Tables  
Table 2-1  VX-150 Doses by [CONTACT_351310] .......................................................................... 4  
Table 3-1  Study VX18 -150-104: Screening Period Prior to Surgery ..................................... 6  
Table 3-2  Study VX18 -150-104: Day -1, Treatment Period and Safety Follow-up ............... [ADDRESS_1237029]  
IXRS  interactive web or voice response system  
max maximum value  
MCP -Mod  multiple comparison procedures with modeling techniques  
MedDRA  Medical Dictionary for Regulatory Activities  
min minimum value  
n number of subjects  
Nav voltage -gated sodium channels  
NPRS  Numeric Pain Rating Scale  
PC publication committee  
PD pharmacodynamic, pharmacodynamics  
PE physical examination  
PI [INVESTIGATOR_244278], pharmacokinetics  
POC  proof -of-concept  

Protocol VX1 8-150-104, Version  2.0 Page 14 of 51 
Vertex Pharmaceuticals Incorporated   Abbreviation  Definition  
prn as needed  
PT Preferred Term  
q12h  every 12 hours  
q2h every 2 hours  
q4h every 4 hours  
qd daily  
QTcF  QT interval corrected by [CONTACT_6550]’s formula  
SAE  serious adverse event  
SAP statistical analysis plan  
SC steering committee  
SD standard deviation  
SE standard error  
SET Study Execution Team  
SPID24  sum of the pain intensity difference [ADDRESS_1237030] common symptoms for which patients seek medical attention. It is a 
protective mechanism designed to prevent tissue injury. When pain persists beyond its usefulness, it becomes pathological and can prove debilitating. Current pain therapi[INVESTIGATOR_884237] a high risk of adverse events (AEs). For example, lidocaine (a nonselective sodium channel blocker) may effectively reduce pain, but its utility is limited because of prominent side effects when given at dose levels required for pain relief.
1 According to 2016 
estimates, more than 42,000 deaths were attributable to opi[INVESTIGATOR_884238], and in Europe, more 
than 80% of fatal drug overdoses involve opi[INVESTIGATOR_2438] .2, 3 The limited treatment options for pain, 
combined with a growing awareness of the risks of the current standards of care, underscore the need for new pain management therapi[INVESTIGATOR_014].  
Voltage-gated sodi um channels (Na
v) play a critical role in pain signaling based on both 
nonclinical and clinical evidence. Evaluation of the role these channels play in normal physiology and the pathological states arising from mutations in sodium channel genes and animal models, as well as the pharmacology of known sodium channel modulating agents, all 
point to the critical role of Na
vs in pain sensation.4-6 The Na v1.8 channel is primarily restricted to 
peripheral neurons that sense pain (e.g., dorsal root ganglia) and is known to mediate pain sensation and chronic pain. For example, Na
v1.[ADDRESS_1237031] not identified target organs of toxicity.  
5.2 Study Rationale  
To date, 5 Phase 1 clinical studies and 2 Phase 2 proof-of-concept (POC) studies have been completed with VX -150. This Phase 2 dose-ranging study was designed to help inform dose 
selection for Phase 3 studies in acute pain.  
Data from clinical and nonclinical studies of VX -150 and the current unmet medical need for 
new treatments for acute pain support clinical development of VX-150. Further details of the 
VX-150 development program are available in the VX- 150 Investigator’s Brochure .
11  
6 STUDY OBJECTIVES  
6.1 Primary Objective  
To evaluate the dose-response relationship of VX-150 in treating acute pain following bunionectomy 

Protocol VX1 8-150-104, Version  2.0 Page 16 of 51 
Vertex Pharmaceuticals Incorporated   6.2 Secondary Objectives 
• To evaluate the safety and tolerability of VX -150 
• To evaluate the pharmacokinetics (PK) of VRT-1207355 and the metabolite VRT-1268114 
(M5)  
7 STUDY ENDPOINTS  
7.1 Primary Endpoint  
Time -weighted sum of the pain intensity difference between VX- 150 versus placebo as recorded 
on a Numeric Pain Rating Scale (NPRS) 0 to 24 hours (SPID24) after the first dose  
7.2 Seconda ry Endpoints  
• Time -weighted sum of the pain intensity difference between VX-150 versus placebo as 
recorded on an NPRS 0 to 48 hours (SPID 48) after the first dose  
• Proportions of subjects with at least 30%, 50%, or 70% reduction in NPRS at [ADDRESS_1237032] dose of VX -150 versus placebo 
• Time to onset of “confirmed perceptible pain relief” and “meaningful pain relief” after the 
first dose of VX -150 versus placebo 
• Plasma PK parameters of VRT -1207355 and the metabolite M5 
• Safety and tolerability based on t he incidence and type of adverse events (AEs), changes 
from baseline in clinically significant laboratory test results, and vital signs at designated 
visits  
8 STUDY POPULATION  
Eligibility will be reviewed and documented by [CONTACT_14465]’s team before subjects are enrolled.  
Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be eligible.  
8.1 Inclusion Criteria  
Before surgery:  
1. Subject will sign and date an informed consent form (ICF) 
2. Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures  
3. Body mass index (BMI) of 18.0 to  38.0 kg/m
2, inclusive 

Protocol VX1 8-150-104, Version  2.0 Page 17 of 51 
Vertex Pharmaceuticals Incorporated   4. Subjects  (male and female) will be between the ages of [ADDRESS_1237033] metatarsal bunionectomy repair, without 
collateral procedures, under regional anesthesia (Mayo and popliteal sciatic block) not to include base wedge procedure  
After surgery:  
6. Subject reported pain of ≥4 on the NPRS and moderate or severe pain on the Verbal Categorical Rating Scale (VRS) within [ADDRESS_1237034] is lucid and able to follow commands. 
8. All analgesic guidelines (Section  9.4.1)  were followed during and after the bunionectomy. 
8.2 Exclusion Criteria  
Before surgery:  
1. History in the past 10 years of malignancy, except for squamous cell skin cancer, basal cell 
skin cancer, and Stage 0 cervical carcinoma in situ (all [ADDRESS_1237035] 5 years)  
2. History of cardiac dysrhythmias requiring anti- arrhythmia treatment(s) , or history or 
evidence of abnormal study ECGs that in the opi[INVESTIGATOR_306000]'s participation in the study 
3. History of abnormal laboratory results ≥2.5 × upper limit of normal (ULN) indicative of any significant medical disease that in the opi[INVESTIGATOR_884239]’s  participation in the study  
4. History of peripheral neuropathy 
5. A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C virus es 
6. Prior medical history of bunionectomy or other foot surgery on the index foot; or bunionectomy on the opposite foot as part of this study 
7. Any prior surgery within [ADDRESS_1237036]’s ability to complete the study, and/or compromise the objectives of the study (e.g., peripheral arterial insufficiency, peripheral edema)  
9. History of peptic ulcer disease, or intolerance or unwillingness to receive ibuprofen 
10. For female subjects: Pregnant, nursing, or planning to become pregnant during the study or within [ADDRESS_1237037] study drug dose  
11. For male subjects: Male subjects with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within [ADDRESS_1237038] for drugs of abuse 
• A positive drug screen for a known prescribed concomitant medication that is not 
otherwise exclusionary (e.g., benzodiazepi[INVESTIGATOR_1651]) will not disqualify subjects; however, 
marijuana will not be allowed .  
14. Subject, or close relative of the subject, is the investigator or a subinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the stud y at that site  
15. Use of restricted medication or food within the specified duration before the first dose of study drug, as defined in Section 9.4 
16. Participation in a previous study investigating VX -150 
After surgery:  
17.  Subject had a type [ADDRESS_1237039] metatarsal bunionectomy 
repair on Day -1 ( Figure  9-1) . A continuous popliteal sciatic block infusion (0.2% ropi[INVESTIGATOR_10319]) 
will be started after surgery and will be removed between 3AM and 5AM on Day 1. After 
removal of the popliteal sciatic block, a subject can be randomized once the subject requests the first dose of study drug for pain relief, and the subject’s pain is ≥[ADDRESS_1237040] will not be eligible to enroll in the study.  
A total of approximately 242 subjects will be randomized 2:2:2:2:1:2 to 6 treatment arms , 
evaluating a range of 5 VX-150 dose levels as shown in Table 9-1.  
Table 9-1 VX-150 Dose s by [CONTACT_884246]-150 1 (highest)  First dose [ADDRESS_1237041] dose 500 mg, then 250 mg q12h  44 
 5 (lowest)  250 mg qd  22 
Placebo    44 
q12h: every 12 hours; qd: daily  
Note: q12h dosing will be th rough [ADDRESS_1237042]  dose of study drug throughout the protocol . 
Randomization will be stratified by [CONTACT_884247]. To maintain the blind, all subjects will receive 
the same number of capsules  in a double- dummy design.  

Protocol VX1 8-150-104, Version  2.0 Page 19 of 51 
Vertex Pharmaceuticals Incorporated   Subjects will report their pain on the NPRS at scheduled time points ( Table 3-2)  through 
[ADDRESS_1237043] dose of study drug to receive rescue medication, and subjects 
should generally not receive rescue medication unless their NPRS is ≥4. However, subjects may receive rescue medication at any time after the first dose of study drug per their request. The rescue medication will be ibuprofen (400 mg [oral] every 4 hours [q4h] a s needed [prn]).  
Figure  9-1 VX18 -150-104 Study Design 
 
CRU: clinical research unit; NPRS: Numeric Pain Rating Scale; VRS:  Verbal Categorical Rating Scale  
Notes:  After removal of the popliteal sciatic block, a subject can be randomized once the subject requests the first 
dose of study drug for pain relief, and the subject’s pain is ≥4 on the NPRS and is moderate or severe on the 
VRS. VX -150 dose levels (Dose Level s 1 [highest], 2, 3, 4, and 5 [lowest]) are shown in  Table  9-1. To maintain 
the blind, all subjects will receive the same number of capsules.  
 
9.1.1  Screening 
Screening Visit assessments required before  the day of surgery are listed in  Table 3-1.  
Screening will occur within 28  days before administration of study drug; this includes the 
screening period before  surgery and the day of surgery (Day -1). The investigator (or an 
appropriate authorized designee at the study site) will obtain informed consent from each subject.  
To prepare for study participation, subjects will be instructed on the study restrictions 
(Section  9.4).  
[IP_ADDRESS]  Repetition of Screening Assessments  
Repetition of any screening assessment that did not meet eligibility criteria is not permitted, unless there is clear evidence of a laboratory error (e.g.,  hemolysis of sample).  

Protocol VX1 8-150-104, Version  2.0 Page 20 of 51 
Vertex Pharmaceuticals Incorporated   [IP_ADDRESS]  Rescreening  
Subjects who do not meet the eligibility criteria may not be rescreened, with the following 
exceptions:  
• Subjects who met all eligibility criteria but had an intercurrent illness (e.g.,  upper respi[INVESTIGATOR_884240]) in the [ADDRESS_1237044] study drug dose that was properly 
evaluated and which resolved fully 
• Subjects who met all eligibility criteria but were not able to obtain required documentation 
within the allotted screening window  
• Subjects w ho met all eligibility criteria but transiently (for personal reasons) are unable to 
commit to all study procedures  
Any subject who is rescreened for any of the exceptions listed above may have the screening 
window extended by [ADDRESS_1237045] has any clinically significant, study -related abnormalities at the conclusion of the 
scheduled inpatient portion of the study, the medical monitor (or authorized designee) will be notified, and the subject will be asked to remain in the clinical research unit (CRU) until such abnormalities resolve. If the subject is unable or unwilling to remain in the CRU, the medical monitor (or authorized designee) will be notified, and the investigator will make every effort to arrange follow -up evaluations at appropriate intervals to document the course of the 
abnormalities.  
9.1.[ADDRESS_1237046] a Safety  Follow-up Phone Interview 7 (±  2) days after the last study drug dose 
for the purpose of collecting information on AEs, medications, and treatments and procedures. A 
visit will only be required if a clinical finding during the Treatment Period requires follow -up. 
9.1.[ADDRESS_1237047] has any clinically significant, study -related abnormalities, the medical monitor 
(or authorized designee) will be notified, and the subject will be asked to remain in the CRU until such abnormalities resolve. If the subject is unable or unwilling to remain in the CRU, the medical monitor (or authorized designee) will be notified, and the investigat or will make every 
effort to arrange follow -up evaluations at appropriate intervals to document the course of the 
abnormalities. See Section  9.8 for additional details on removal of subjects. 
Subjects who prematurely discontinue study drug dosing will complete the Safety Follow-up Phone Interview 7 (± 2) days after the last study drug dose for the purpose of collecting 
information on AEs, medications, and treatments and procedures. A visit will only be required if a clinical finding during the Treatment Period requires follow -up. 

Protocol VX1 8-150-104, Version  2.0 Page 21 of 51 
Vertex Pharmaceuticals Incorporated   9.2 Method of Assigning Subjects to Treatment Groups  
An interactive voice response system (IXRS) will be used to assign subjects to treatment. The 
randomization code will be produced by [CONTACT_14448] a qualified randomization vendor. The Vertex study biostatistician will review and approve the production of the final randomization list, which will be reviewed and approved by a designated unblinded biostatistician who is not a member of the study execution team.  
9.[ADDRESS_1237048] of VX -150 on acute surgical pain. Bunionectomy is a 
well-established, multi-dose, surgical, acute pain model. A randomized, double-blind study 
design was selected to avoid observer bias and reduce symptoms or outcomes arising from the subjects’ knowledge of treatment. A range of VX -[ADDRESS_1237049]’s pain meets the pain threshold criteria. The pain threshold criteria are designed to ensure subjects have sufficient pain to determine if the drug is effective. Ibuprofen was selected as the rescue medication because it is a commonly used, short -acting, 
standard -of-care treatment for acute pain.  
9.3.2  Study Drug Dose and Duration 
Five dose levels of VX -150 (Dose Level s 1 [highest], 2, 3, 4, and 5 [lowest]) will be evaluated  as 
shown in Table 9-1. The highest dose level ( Dose Level 1 [first dose 1500 mg, then 750 mg 
every 12 hours (q12h)]) will not exceed a maximum dose o f 2250 mg per day. The maximum 
dose has been selected on the basis of favorable safety and VRT -1207355 PK results after oral 
dosing with VX-150 in  
VX16 -150-103 (Study 103). Multiple oral doses up to [ADDRESS_1237050] dose level (Dose Level 1 ) to be tested (2250 mg per day; first dose 1500 mg 
followed by [CONTACT_195823] 750 mg q12h) was evaluated in Study [ADDRESS_1237051] dose of VX-150 on Day 1 and Day 2, the mean VRT -1207355 maximum observed concentration (C
max) of 4.95 µg/mL ( Day 1) and 
4.92 µg/mL (Day  2) exceeded the concentration resulting in 50% of the maximum inhibition 
(IC50) for inhibition of Na v1.8. The maximum concentrations for VRT-[ADDRESS_1237052] and 
second doses, favoring VX-150 compared to placebo. VX- 150 was generally well tolerated in 
these subjects without any significant safety concerns.  
9.3.3  Rationale for Study Assessments  
11-point (0  to 10) Numeric Pain Rating Scale: NPRSs are frequently used in bunionectomy 
studies and are recognized by [CONTACT_4760] a valid pain intensity measure.
12 

Protocol VX1 8-150-104, Version  2.0 Page 22 of 51 
Vertex Pharmaceuticals Incorporated   4-point Verbal Categorical Rating Scale:  A VRS (none, mild, moderate, or severe) is included 
as part of the pain threshold inclusion criterion to ensure that all subjects are experiencing 
moderate or severe pain at baseline. Moderate or severe pain at baseline ensures subjects have sufficient pain to determine if the drug is effective.  
Double -stopwatch assessment: The double- stopwatch assessment is a standardized assessment 
for determining the onset of pain relief .
13, [ADDRESS_1237053] feel “perceptible pain relief,” and to stop the second watch when they first feel “meaningful pain relief.” 
9.[ADDRESS_1237054] of study restrictions will be provided in the Study Reference Manual. 
Table 9-2 Study Restrictions  
Restricted 
Medication/Food/Activitya Timing of Restriction  
From ( Minimum)  To 
Other  investigational drugs or 
devices  [ADDRESS_1237055] study drug 
dose, or time determined by [CONTACT_2243]; whichever is longer  Completion of Safety Follow -up  
Analgesic medications  Starting [ADDRESS_1237056] study drug dose  Until discharge from CRU  
Grapefruit or grapefruit juice, 
pomelos, star fruit; Seville 
oranges  [ADDRESS_1237057] green family 
(e.g., kale, broccoli, watercress, 
collard greens, kohlrabi, Brussels 
sprouts, mustard), and charbroiled 
meats  [ADDRESS_1237058] PK sample is taken  

Protocol VX1 8-150-104, Version  2.0 Page 23 of 51 
Vertex Pharmaceuticals Incorporated   Table 9-2 Study Restrictions  
Restricted 
Medication/Food/Activitya Timing of Restriction  
From ( Minimum)  To 
Alcohol  24 hours before admission to the CRU  Until discharge from CRU  
Strenuous exercise (e.g.,  heavy 
lifting, weight training, and 
aerobics)  [ADDRESS_1237059] clinical 
laboratory testing  Completion of Safety Follow -up  
CRU: clinical research unit; PK: pharmacokinetics  
a Refer to the Study Reference Manual for a more complete list of medications prohibited/restricted in the study. 
See Section  9.5 for guidance on concomitant medications.  
9.4.1  Analgesic Medications 
• Apart from standard of care during admission, opi[INVESTIGATOR_884241] 2 days before 
admission on Day -1 through discharge on Day 3.  
• Perioperative pain management will follow the standard of care, becoming progressively more conservative before removal of the popliteal sciatic block:  
o Preoperatively, IV midazolam and/or fentanyl will be administered, followed by [CONTACT_884248], a popliteal sciatic block (0.5% ropi[INVESTIGATOR_10319]), and a Mayo block (2% lidocaine without epi[INVESTIGATOR_238]).  
o A continuous popliteal sciatic block infusion (0.2% ropi[INVESTIGATOR_10319]) will be started after surgery and will be removed between 3AM and 5AM on Day 1. 
o After surgery and before removal of the popliteal sciatic block: 
− The use of ice packs is required until removal of the popliteal sciatic block . 
− IV ketorolac can be administered q6h as needed until 6 hours before removal 
of the popliteal sciatic block for subjects with NPRS score of 4 through 6 after 
surgery. 
− Morphine sulfate 2- to 4- mg IV dose can be administered  every 2 hours (q2h) 
as needed until 1.5 hours before removal of the popliteal sciatic block for subjects with NPRS score of 7 or above after surgery. 
− Bolus ropi[INVESTIGATOR_884242]. 
• No pain treat ments are allowed between removal of the popliteal sciatic block and the first 
dose of study drug 
• Rescue medication:  
o Subjects are encouraged to wait [ADDRESS_1237060] dose of study drug to receive rescue medication, and subjects should generally not receive rescue 

Protocol VX1 8-150-104, Version  2.0 Page 24 of 51 
Vertex Pharmaceuticals Incorporated   medication unless their NPRS is ≥4. However, subjects may receive rescue 
medication at any time after the first dose of study drug per their request.  
o The rescue medication will be ibuprofen (400 mg [oral] q4h prn).  
o A record will be kept  of all rescue medication use, and an unscheduled NPRS 
assessment will be completed immediately before each administration of rescue medication.  
9.4.2  Additional Dietary Restrictions  
• Subjects will abstain from all food and drink (except water) at least 4  hours before the 
screening serum chemistry assessment.  
• On Day 1, subjects will be on a clear liquid diet until 11 hours after removal of the popliteal 
sciatic block  (i.e., 2 hours after the end of the randomization window). Doses administered 
after the end of th e clear liquid diet period can be administered without regard to meal 
timings.  
9.5 Prior and Concomitant Medications  
• Subjects will abstain from all concomitant medications as described in Exclusion Criterion  14 and Table 9-2. 
• All opi[INVESTIGATOR_660312] 12 months of Screening Visit will be recorded with  
indication, route of administration, and start and stop dates of administration. 
• All medications taken from 14  days before the Screening Visit through the end of the study 
will be recorded with indication, route of administration, and start and stop dates of 
administration.  
• A female subject of childbearing potential using hormonal contraceptives does not need to 
stop taking hormonal contraceptives; however, they are not considered an approved form of 
contraception (Section [IP_ADDRESS]).  
9.6 Administration  
Study drug will be administered as follows:  
• Doses for the 5 VX -150 treatment arms are shown in  Table 9-1. The total maximum daily 
dose will not exceed 2250 mg (1500 mg loading dose followed by [CONTACT_195823] 750 mg q12h). 
• VX-150 arms will receive a combination of VX-150 and VX-150 placebo capsules. 
• Placebo arm will receive only VX -150 placebo.  
• To maintain the blind, all subjects will receive the same number of capsules.  All subjects will 
receive [ADDRESS_1237061] dose and 4 capsules for the remainder of the dosing period. 
Additional details on dispensing will be included in the Pharmacy Manual. 

Protocol VX1 8-150-104, Version  2.0 Page 25 of 51 
Vertex Pharmaceuticals Incorporated   • Study drug will be administered as described above, with the final dose of VX-[ADDRESS_1237062] dose. 
• Study drug will be administered orally with approximately 240 mL (8  fluid ounces) of water. 
• Subjects will swallow the study drug whole and will not chew the drug before swallowing. 
• Study drug must be administered following the food restrictions outlined in Section  9.4.2. 
9.7 Dose Modification for Toxicity  
If any unacceptable toxicity arises, individual subjects will discontinue dosing (Section 9.1.4).  
9.[ADDRESS_1237063] participate in a Safety Follow -up Phone Interview, if 
applicable (see Section  9.1.4) , and follow up with the subject regarding any unresolved AEs. 
If a subject withdraws consent for the study, no further assessments will be performed. Vertex may retain and continue using the study data and samples after the study ends and may use the samples and information in the development of the study compound, for other drugs and diagnostics, in publications and presentations, and for education purposes. If a subject withdraws 
from the study, the study data and samples collected will remain part of the study. A subject will 
not be able to request the withdrawal of his/her information from the study data. A subject may request destruction of the samples collected from him/her during the study as long as those samples can be identified as his/her samples.  
9.9 Replacement of Subjects  
Subjects who withdraw or are withdrawn for nonsafety reasons during the study drug treatment period(s) may be replaced at Vertex’s discretion.  
[ADDRESS_1237064]  or designated study site staff , and following national and local laws and regulations. 

Protocol VX1 8-150-104, Version  2.0 Page 26 of 51 
Vertex Pharmaceuticals Incorporated   10.2 Packaging and Labeling 
Vertex will supply the 250 -mg VX -150 capsules and matching placebos. Study drug labeling 
will be in compliance with applicable local and national regulations. Additional details regarding 
packaging, labeling, and dispens ing for VX -150 will be included in the Pharmacy Manual. 
10.3 Study Drug Supply, Storage, and Handling 
The investigator, or an authorized designee (e.g., a licensed pharmacist), will ensure that all 
investigational product is stored in a secured area, under recommended storage conditions, and in accordance with applicable regulatory requirements. Specifically, study drug will be stored at [LOCATION_002] Pharmacopeia controlled room temperature in a securely locked, substantially constructed cabinet or other securely locked, substantially constructed enclosure. Access to study drug will be limited to prevent theft or diversion of the study drug. To ensure adequate records, all study drugs will be accounted for via the drug accountability forms as instructed by [CONTACT_139383]. Table 10-1 lists the storage conditions for the capsules. 
Table 10-1 Study Drug  
Drug Name  [CONTACT_824091]/Route  Dosage  How Supplied  
VX-150  Capsule/Oral  ≤2250  mg per day  Supplied as 250 -mg capsules  
VX-150 placebo  Capsule/Oral  None  Supplied as capsule  
 
10.[ADDRESS_1237065] or designated study site staff will maintain information regarding the dates and 
amounts of (1) study drug received and (2) study drug dispensed to the subjects. These materials will be retained at the site according to instructions provided by [CONTACT_139411]. The study monitor will review study drug records and inventory throughout the study. If a site uses a site-specific Drug Accountability System and/or process, including processes associated with the 
destruction of returned materials, the process must be documented and approved by [CONTACT_139383]. The study monitor must review the drug accountability documentation on a regular basis. The study monitor will promptly communicate to Vertex any discrepancies he/she is unable to resolve with 
the site.  
10.[ADDRESS_1237066] supervision of the investigator or designee. A hand- and-mouth check will be done after 
each dose administrati on in the CRU to ensure 100% study treatment compliance. 
10.[ADDRESS_1237067] treatment assignments except for the following 
individuals:  
• Any site personnel for whom this information is important to ensure the safety of the subject 
in the event of a life- threatening medical emergency  
• Any site personnel for whom this information is important to ensure the safety of the subject and the fetus in the event of a pregnancy 
• Vertex Global Patient Safety (GPS) and Regulatory Affairs personnel to satisfy serious 
adverse event (SAE) processing and reporting regulations 
• External vendor (unblinded) statistician preparing the final (production) randomization list 
who is not part of t he study team  
• Vertex IXRS Management for IXRS oversight and system administration  
• Vertex Clinical Supply Chain  
• The bioanalytical contract research organization ( CRO ) laboratory/vendor personnel 
managed by [CONTACT_884249]  
• The Vertex bioanalytical personnel responsible for reviewing raw data from the bioanalytical 
CRO, who is not a member of the Study Execution Team  (SET; the Vertex bioanalytical SET 
member will continue to be blinded) 
Vertex medical monitor may, for matters relating to safety, unblind individual subjects at any 
time.  
A Vertex Modeling & Simulations and Biomarker scientist may be unblinded to individual subject PK data for conducting PK/pharmacodynamic ( PD) analyses. In addition, a Vertex 
clinical pharmacologist will be partially unblinded  to help in management of the PK workspace 
and ensure that only the blinded PK dataset is being provided for preliminary analysis. These individuals will not be a member of the study team and  will not interact with the CRU or study 
personnel. No unblinded data or results of unblinded analyses will be shared with the CRU or with blinded Vertex personnel. Masked IDs will be used for PK and PK/PD analyses. All instances of unblinding by [CONTACT_351587]. 
10.7.[ADDRESS_1237068]'s treatment by [CONTACT_14450]'s study treatment is 
necessary for clinical management. In such cases, investigators will use their best judgment as to whether to unblind without first attempting to contact [CONTACT_460411]. If investigators deem it not necessary to unblind immediately, they will first attempt to contact [CONTACT_14451]. If investigators have tried but are unable to reach the medical monitor, they will use their best judgment, based on the nature and urgency of the clinical situation, and may proceed with unblinding without having successfully reached and discussed the situation with the medical 

Protocol VX1 8-150-104, Version  2.[ADDRESS_1237069] information for the medical monitor (or appropriate backup) will be provided in a 
separate document.  
In addition, the Vertex Medical Information Call Center  will answer calls 
[ADDRESS_1237070]'s treatment assignment has been unblinded for a medical emergency or urgent clinical 
situation, the medical monitor will be notified within [ADDRESS_1237071]'s study file. Information about the tre atment assignment obtained from the unblinding will be maintained in a 
secure location with controlled access and will not be shared with the sponsor (Vertex), the CRO, or any site personnel (other than the physician treating the subject). In addition, the 
investigator will consider whether the clinical event that prompted unblinding will be considered an SAE, according to the regulatory definitions or criteria for SAEs, and if so, submit an SAE report to Vertex GPS or designee, per Section 13.1.2. 
Vertex GPS or designee will also unblind any SAE reports in compliance with regulatory 
reporting requirements. In addition, Vertex may, for matters relating to safety concerns, unblind individual subjects at any time.  
[ADDRESS_1237072] and disease characteristics include the following: demographics, medical history, height, 
and weight . 
11.[ADDRESS_1237073] nominal time relative to dosing. Acceptable windows for sampling time s are shown in Table 11-1. Samples collected outside of 
these acceptable windows will be considered protocol deviations. The following will be recorded accurately in the source document on days of PK blood sample collection: date and time of administration of each dose; date and time of the taking of each PK blood sample; and date and time of the last meal taken before each dose.  

Protocol VX1 8-150-104, Version  2.[ADDRESS_1237074] study drug dose on Day  1 
Predose on Day  2 -15 minutes  
From 1 up to 12  hours after study drug dosing  ±[ADDRESS_1237075] operating procedures. A description of the assay and validation data will be provided in separate reports. 
11.4 Efficacy  
Pain scales: After removal of the popliteal sciatic block, a subject can be randomized once the 
subject requests the first dose of study drug for pain relief, and the subject’s pain is ≥[ADDRESS_1237076] will not be eligible 
for the study. 
Subjects will report their pain on the NPRS at scheduled time points ( Table 3-2)  through 
[ADDRESS_1237077].  

Protocol VX1 8-150-104, Version  2.0 Page 30 of 51 
Vertex Pharmaceuticals Incorporated   Double -stopwatch assessment: At the time of first dose, 2  stopwatches will be started: 1  labeled 
“perceptible pain relief” and the other labeled “meaningful pain relief.” Subjects will stop the 
“perceptible pain relief” stopwatch when/if they feel any pain relief at all and stop the “meaningful pain relief” stopwatch when/if they feel relief that is “meaningful” to them. If the subject does not stop both stopwatches by [ADDRESS_1237078] dose, or receives rescue medication, the stopwatches will be stopped.  
11.5 Safety  
Safety evaluations will include AEs, clinical laboratory assessments, clinical evaluation of vital 
signs, ECGs, and physical examinations (PEs). 
11.5.[ADDRESS_1237079] results that are abnormal and considered clinically 
significant will be reported as AEs (see Section  13.1).  
The safety laboratory test panels are shown in  Table 11-2. 

Protocol VX1 8-150-104, Version  2.[ADDRESS_1237080] bilirubin  
Alkaline phosphatase  
Aspartate aminotransferase 
(=SGOT)  
Alanine aminotransferase (=SGPT)  
Amylase  
Lipase  
Gamma -glutamyl transferase  
Protein  
Albumin  
Creatine kinase  
Urate  Hemoglobin  
Erythrocytes  
Mean corpuscular volume  
Platelets  
Leukocytes  
Differential (absolute and percent):  
Eosinophils  
Basophils  
Neutrophils  
Lymphocytes  
Monocytes  
Coagulation  
Activated partial thromboplastin time  
Prothrombin time  
Prothrombin time International Normalized Ratio  Urobilinogen  
Urine protein  
pH 
Urine blood  
Specific gravity  
Urine ketones  
Urine bilirubin  
Urine glucose  
Note: Screening Visit blood draws will be done after a minimum [ADDRESS_1237081] to receive study drug on Day 1. 
Additional Tests at Screening: The following additional tests will be performed during screening 
to assess eligibility:  
Serum follicle -stimulating hormone: Serum follicle -stimulating hormone will be tested at 
screening for female subjects who are suspected to be postmenopausal. For a subject to be considered  of non- childbearing potential, the serum follicle -stimulating hormone levels will be 
within the laboratories’ range for postmenopausal females. 
Pregnancy testing: All female subjects must have a Screening serum pregnancy test within 
7 days before Day  1. Female subjects of childbearing potential (as defined in Section  [IP_ADDRESS]), 
must also have a Day -[ADDRESS_1237082] be negative to receive study drug.  
Drug and alcohol screening (Screening Visit and Day - 1): Opi[INVESTIGATOR_858], methadone, cannabinoids, 
cocaine, amphetamines/methamphetamines, barbiturates, and benzodiazepi[INVESTIGATOR_306003] a urine test. Subjects may also undergo random urine drug screening and alcohol testing if 
deemed appropriate by [CONTACT_093]. The drug test at Screening and Day  -[ADDRESS_1237083] to receive study drug. A positive drug screen for a known prescribed concomitant 
medication that is not otherwise exclusionary (e.g.,  benzodiazepi[INVESTIGATOR_1651]) will not disqualify subjects; 
however, marijuana will not be allowed. 
Additional evaluations: Additional clinical laboratory evaluations will be performed at other 
times if judged to be clinically appropriate.  
With the exception of the Day -[ADDRESS_1237084] value 
is found to be abnormal and clinically significant, it will be verified by [CONTACT_884250]. If it is not possible 
to send a timely specimen to the central laboratory (e.g.,  the subject was hospi[INVESTIGATOR_94248]), 
the investigator may base the assessment of an AE on the local laboratory value.  
11.5.[ADDRESS_1237085] 
study visits (Table 3-1 and Table 3-2) . At other visits, symptom- directed PEs and 
symptom- directed vital signs assessments can be performed at the discretion of the investigator 
or healthcare provider. 
A PE includes a review of t he following systems: head, neck, and thyroid; eyes, ears, nose, and 
throat (EENT); respi[INVESTIGATOR_696]; cardiovascular; lymph nodes; abdomen; skin; musculoskeletal; and neurological. Breast, anorectal, and genital examinations will be performed when medically indicated. After screening, any clinically significant abnormal findings in PEs will be reported as AEs.  
Vital signs include blood pressure (systolic and diastolic), temperature, pulse rate, and respi[INVESTIGATOR_1487]. Vital signs will be assessed in the supi[INVESTIGATOR_884243] [ADDRESS_1237086] 12-lead ECGs will be performed using a machine with printout ( Table 3-1 and 
Table 3-2) . Additional standard 12- lead ECGs will be performed at any other time if clinically 
indicated. The performance of all ECGs will adhere to the following guidelines: 
• The ECG will be done before any other procedures that may affect heart rate, such as blood 
draws.  
• The subject will be instructed to rest for at least 5  minutes before having an ECG. 
• The test should be performed in the supi[INVESTIGATOR_2547] 
A printout of the ECG traces will be made for safety review by [CONTACT_168795]. Clinically significant ECG abnor malities occurring during the study 
through the Safety Follow-up Phone Interview will be recorded as AEs. 
To ensure safety of the subjects, a qualified individual at the study site will make comparisons to 
baseline measurements. If the QTcF is increased by  >60 msec from the baseline or an absolute 
QTcF value is ≥500 msec for any scheduled ECG, 2 additional ECGs will be performed approximately 2  to 4 minutes apart to confirm the original measurement. If either of the QTcF 

Protocol VX1 8-150-104, Version  2.0 Page 33 of 51 
Vertex Pharmaceuticals Incorporated   values from these repeated ECGs remains above the threshold value (>60 msec from baseline or 
≥500 msec), a single ECG will be repeated at least hourly until QTcF values from [ADDRESS_1237087] with a QTcF value ab ove the threshold value will discontinue dosing. 
11.5.5  Contraception and Pregnancy  
[IP_ADDRESS]  Contraception 
At this stage in the development of VX-150, study participation requires a commitment from the subject that he/she and subject's respective partner use [ADDRESS_1237088] dose of study drug. Additional contraception requirements may need to be followed according to local regulations and/or requirements. 
The contraception requirement for the couple is waived for the following: 
• True abstinence for the subject, when this is consistent with the preferred and usual lifestyle 
of the subject. True abstinence must be practiced from the Screening Visit through [ADDRESS_1237089] dose of study drug. Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.  
• If the male is infertile (e.g., bilateral orchiectomy). Infertility may be documented through 
examination of a semen specimen.  
• If the female is of non -childbearing potential. To be considered of non-childbearing potential, 
the female must meet at least 1 of the following criteria: 
o Postmenopausal: Amenorrheic for at least 2 years and a serum follicl e-stimulating 
hormone level within the laboratory's reference range for postmenopausal females 
o Documented bilateral oophorectomy and/or hysterectomy 
• Same sex relationships.  
Unique situations that may not fall within the above specifications may be discusse d with the 
sponsor’s medical monitor or designee on an individual basis. 

Protocol VX1 8-150-104, Version  2.0 Page 34 of 51 
Vertex Pharmaceuticals Incorporated   Table 11-3 Acceptable Methods of Contraception  
Contraceptive Method  Male Subjects and  
Their Female Partners  Female Subjects and  
Their  Male Partners  
Documented vasectomy (with a 
negative sperm postvasectomy 
semen analysis) at least 6 months before the study drug dose  Yes Yes 
Condom with spermicide (either as a 
single product if commercially available and/or allowed according 
to local regulations; otherwise 
condom and spermicide as separate 
products).  Yesa Yesa 
Documented bilateral tubal ligation 
performed at least [ADDRESS_1237090] dose of study drug  Yes Yes 
Continuous use of an intrauterine 
device (nonhormone -releasing) for 
at least [ADDRESS_1237091] of childbearing potential using hormonal contraceptives does not need to stop taking 
hormonal contraceptives; however, they are not considered an approved form of contraception.  
[IP_ADDRESS]  Pregnancy  
Subjects will be counseled to inform the investigator of any pregnancy that occurs during study 
treatment and up to [ADDRESS_1237092] becomes pregnant while participating in the study, study drug will be permanently discontinued immediately. The investigator will notify the medical monitor and Vertex GPS within 24 hours of the site's knowledge of the subject's (or 
partner's) pregnancy using the Pregnancy Information Collection Form. 
If confirmed to be on active drug, the subject or partner will be followed for safety (adverse 
events) until the end of the pregnancy and similarly, the infant will be followed for [ADDRESS_1237093] dose (SPID 24). The primary analysis of this endpoint is to detect if there 
is a significant dose -response relationship across VX-150 dose groups and placebo using the 
MCP -Mod (multiple comparison procedures with modeling techniques). Under MCP-Mod, a 

Protocol VX1 8-150-104, Version  2.0 Page 35 of 51 
Vertex Pharmaceuticals Incorporated   pre-specified c andidate set of 4 dose- response models (Linear, Emax, Logistic , and Sigmoid E max) 
is proposed. 
Assuming the maximum effect size compared to placebo is 0.7, 40 evaluable subjects in the 
placebo, VX-150 Dose Level 1 (highest), 2, 3, and 4 groups, and 20 evaluable subjects in VX-150 Dose Level 5 (lowest) group would provide approximately at least 88% power to detect a dose-response relationship from the candidate set with a 5% level of significance. In addition, [ADDRESS_1237094] 85% power to detect an effect size 
of 0.7 compared to placebo. In order to allow for withdrawal of up to 10% of randomized subjects, the study will enroll and randomize approximately [ADDRESS_1237095] listin gs and disposition 
summary table, unless otherwise specified. 
The Full Analysis Set (FAS) is defined as all randomized subjects who have received at least 
[ADDRESS_1237096] 1 dose of study drug and for 
whom the primary PK data are considered to be suf ficient and interpretable.  
12.3 Statistical Analysis  
The primary objective of this study is to evaluate the dose-response relationship of VX-150 in treating acute pain following bunionectomy. 
This section presents a summary of the planned statistical analyses of efficacy and safety for this 
study. The Vertex Biometrics department or a designated CRO will analyze the data derived from this study. Statistical Analysis System Version 9.4 or higher and R Version 3.5.0 or higher will be used to generate all statistic al outputs (tables, figures, listings, and data sets). 
Statistical analysis and presentation details will be provided in the Statistical Analysis Plan (SAP) for the study.  
12.3.[ADDRESS_1237097] data for all individual subjects randomized or exposed to study drug will 
be presented in data listings. Continuous data will be summarized using the following descriptive summary statistics: the number of subjects (n), mean, SD, median, minimum value (min), and maximum value (max). Categ orical data will be summarized using counts and percentages. 

Protocol VX1 8-150-104, Version  2.[ADDRESS_1237098] recent non- missing 
measurement (scheduled or unscheduled) collected before the initial administration of study 
drug. 
12.3.2  Backgr ound Characteristics  
[IP_ADDRESS]  Subject Disposition  
The disposition summary will be based on the All Subjects Set. 
The number and percentage of subjects in each of the following disposition categories will be 
summarized based on the FAS: completed treatment, prematurely discontinued the treatment and the reason for discontinuation, completed study, and prematurely discontinued study, with a breakdown of the reasons for discontinuation. 
[IP_ADDRESS]  Demographics and Baseline Characteristics  
The following demographics and baseline c haracteristics will be summarized by [CONTACT_155427]: sex, age, race, ethnicity, weight, height, BMI, and pain intensity. 
No statistical tests will be carried out to evaluate any baseline imbalance between treatment 
groups. 
[IP_ADDRESS]  Prior and Concomitant Medications  
Medications taken 14 days before the Screening Visit and up to the Safety Follow-up Phone 
Interview will be summarized by [CONTACT_306027] -Drug 
Dictionary (WHO -DD) for the FAS as frequency tables in 2 pa rts: 
Prior medication : Medication that started before the first dose of study drug, regardless of when 
dosing of the medication ended. 
Concomitant medication : Medication received at or after the first dose of study drug, 
medication that was received before initial dosing and continued after initial dosing of study 
drug, or medication with missing stop date. 
Medication that started before the first dose of study drug and continued after the first dose of 
study drug will be summarized as prior medication and separately as concomitant medication. Medications with a missing start date will be considered to have a start date before the first dose of study drug. 
[IP_ADDRESS]  Study Drug Exposure and Compliance  
Study drug will be administered to the subjects by [CONTACT_884251] 3-2 and as described in Section 9.6. All data collected during dispensation of study drug (i.e., time of intake and number of capsules taken) will be presented in data listings only. 
12.3.3  Efficacy Analysis  
Evaluation of the dose-response of the efficacy of VX-150 is the primary objective of this study. 
All efficacy endpoints will be analyzed based on the FAS. 
[IP_ADDRESS]  Analysis of Primary Variable  
The primary efficacy endpoint is the time -weighted sum of the pain intensity difference between 
VX-150 versus placebo as recorded on a N umeric Pain Rating Scale (NPRS) 0 to 24 hours 
(SPID 24) after the first dose. The primary efficacy analysis will be using the MCP -Mod 

Protocol VX1 8-150-104, Version  2.[ADDRESS_1237099] the dose-response relationship from a candidate set of 4 dose-response models 
(Linear, Emax, Logistic , and Sigmoid E max). Two -sided P  value for each dose-response model will 
be provided.  
Both MCP-Mod approach  in SPID24 between VX -150 and placebo 
will be based on an analysis of covariance (ANCOVA) model. The model will include the time-
weighted sum of the pain intensity difference 0 to 24 hours (SPID24 ) after the first dose as the 
dependent variable, and treatment as a fixed effect, with adjustment for stratification factors, i.e., site and sex, and baseline pain as a covariate.  
Pain intensity scores that were collected within [ADDRESS_1237100] before the calculation of SPID24 values.  
 
[IP_ADDRESS]  Analysis of Secondary Efficacy Variables  
• Time -weighted sum of the pain intensity difference between VX-150 versus placebo as 
recorded on a NPRS 0 to 48 hours (SPID48 ) after the first dose:  analysis of this variable will 
be similar to the primary analysis.  
• Proportions of subjects with at least 30%, 50%, or 70% reduction in NPRS at [ADDRESS_1237101] dose of VX-150 versus placebo: This variable will be analyzed using the 
Cochran -Mantel -Haenszel test, stratified by [CONTACT_884247].  
• Time to onset of “confirmed perceptible pain relief” after the first dose of VX -150 versus 
placebo: This variable will be analyzed using Cox regression model. The model will include a covariate for treatment and adjustment for site and sex. Additionally, the Kaplan- Meier 
method will be used to produce graphical presentation of the survival curves by [CONTACT_884252]. 
• Time to onset of “meaningful pain relief” after the first dose of VX -150 versus placebo: The 
analysis of this variable will be similar to the analyses of time to onset of “perceptible pain relief .” 

Protocol VX1 8-150-104, Version  2.0 Page 38 of 51 
Vertex Pharmaceuticals Incorporated   12.3.4  Safety Analysis 
The overall safety profile of VX -150 will be assessed in terms of the following safety and 
tolerability endpoints: 
• Incidence of treatment -emergent adverse events (TEAEs)  
• Clinical laborato ry values (hematology, serum chemistry, coagulation studies, and urinalysis) 
• ECG outcomes 
• Vital signs  
Safety endpoints will be analyzed based on the Safety Set.  
All safety data will be presented in individual subject data listings.  
[IP_ADDRESS]  Adverse Events 
AEs will be coded according to MedDRA. The number and percentage of subjects experiencing 
an AE will be summarized by [CONTACT_306029]  (PT), as 
well as by [CONTACT_1570]. AEs will be classified as pretreatment or treatment- emergent as 
follows:  
Pretreatment AEs  are defined as AEs that occurred  or worsened after signing the ICF up to the 
start of study dosing. 
Treatment -emergent AEs are defined as AEs that occurred  or worsened on or after the start of 
drug dosing through the Safety Follow- up. Only TEAEs will be summarized in tables. All 
summaries  of TEAEs will be presented by [CONTACT_884253]. Some rules that will apply to the summarization of AEs are (1) a subject with multiple 
occurrences of the same AE or a continuing AE will only be counted once; (2) only the maximum severity level will be presented in the severity summary; and (3) only the worst 
relationship level will be  presented in the relationship summary. 
SAEs and AEs leading to death, dose interruption, and permanent discontinuation will be listed 
separately. All AEs through Safety Follow- up will be listed in an individual subject data listing, 
including pretreatment AEs.  
[IP_ADDRESS]  Clinical Laboratory Assessments  
All statistical analyses of laboratory values will be performed using the International System of 
Units. Hematology and clinical chemistry results at baseline will be summarized by [CONTACT_1570]. Other assessments w ill be collected as needed (i.e., at unscheduled visits).  
A listing containing individual subject hematology and clinical chemistry measurements outside the threshold value criteria at any visit will be provided. For each subject in the listing, measuremen ts at all visits will be included. The threshold value criteria for clinical laboratory 
data will be provided in the SAP. Results of coagulation, urinalysis, and the urine/serum pregnancy test will be presented in individual subject data listings only. Cli nically significant 
abnormal laboratory findings will be reported as AEs. 
[IP_ADDRESS]  Electrocardiogram  
A summary of raw values and change from baseline values will be provided by [CONTACT_884254]: PR, QT, QRS, and QTcF 

Protocol VX1 8-150-104, Version  2.0 Page 39 of 51 
Vertex Pharmaceuticals Incorporated   intervals and heart rate. In addition, the number and percentage of subjects by [CONTACT_884255]-treatment value of QT/QTcF intervals, categorized as ≤450 msec, >450 msec and ≤480 msec, >480 msec and ≤500 msec, and >500 msec, as well as maximum on- treatment change from 
baseline value of QT/QTcF intervals, categorized as ≤30 msec, >30 and ≤60 msec, and >[ADDRESS_1237102] in the listing, measurements at all time points will be included. Clinically significant abnormal findings will be reported as AEs.  
[IP_ADDRESS]  Vital Signs  
The following vital signs will be summarized by [CONTACT_313311]: systolic and diastolic blood pressure (mm Hg), body temperature (°C), pulse rate (beats per minute), and respi[INVESTIGATOR_697] (breaths per minute).  
A listing containing individual vital signs measurements that are outside the threshold values criteria at any visit will be provided. For each subject in the listing, measurements at all visits will be included. Clinically significant abnormal findings in vital signs will be reported as AEs.  
[IP_ADDRESS]  Physical Examination  
PE results will be presented in individual subject data listings only. Clinically relevant results identified after screening will be reported as AEs.  
[IP_ADDRESS]  Other Safety Analysis 
Not applicable.  
12.3.[ADDRESS_1237103] concentrations. 
Details of the analyses will be in the clinical pharmacology analysis plan ( CPAP ). 
12.4.2  Pharmacokinetic/Pharmacodynamic Analyses  
A population PK analysis of plas ma concentration versus time data of VRT -1207355 may be 
performed using the nonlinear mixed-effects modeling approach. A population approach may 
also be used to investigate the exposure-response relationship for the efficacy and safety variables. A more detailed description of the methodology to be followed will be presented in the Population PK/PD Analysis Plan. The results of the population PK and PK/PD analysis (if done) will be reported in a separate document. 

Protocol VX1 8-150-104, Version  2.0 Page 40 of 51 
Vertex Pharmaceuticals Incorporated   13 PROCEDURAL, ETHICAL,  REGULATORY, AND ADMI NISTRATIVE 
CONSIDERATIONS  
13.1 Adverse Event and Serious Adverse Event Documentation, Severity 
Grading, and Reporting 
13.1.1  Adverse Events 
[IP_ADDRESS]  Definition of an Adverse Event  
An AE is defined as any untoward medical occurrence in a subject during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or worsening of a pre-existing condition (e.g., increase in its severity or frequency) after the ICF is signed.  
An AE is considered serious if it meets the definition in Section [IP_ADDRESS]. 
[IP_ADDRESS]  Clinically Significant Assessments 
Study assessments including laboratory tests, ECGs, PEs, and vital signs will be assessed and 
those deemed to have clinically significant worsening from baseline will be documented as an AE. When possible, a clinical diagnosis for the study assessment will be provided, rather than the abnormal test result alone (e.g.,  urinary tract  infection, anemia). In the absence of a diagnosis, 
the abnormal study assessment itself will be listed as the AE (e.g.,  bacteria in urine or decreased 
hemoglobin). 
An abnormal study assessment is considered clinically significant if the subject has 1  or more of 
the following: 
• Concomitant signs or symptoms related to the abnormal study assessment 
• Further diagnostic testing or medical/surgical intervention  
• A change in the dose of study drug or discontinuation from the study 
Repeat testing to determine whether the result is abnormal, in the absence of any of the above 
criteria, does not necessarily meet clinically significant criteria. The determination of whether the 
study assessment results are clinically significant will be made by [CONTACT_093].  
A laboratory value that is Grade [ADDRESS_1237104]’s clinical status indicates a life -threatening AE.  
[IP_ADDRESS]  Documentation of Adverse Events  
All AEs will be collected from the time the ICF is signed until the following times: 
• For subjects who do not enroll: until time of screen failure (e.g., screen failure, withdrawal of 
consent) 
• For enrolled subjects who have a Safety Follow-up Phone Interview: through the Safety 
Follow-up Phone Interview 
• For enrolled subjects who do not have a Safety Follow-up Phone Interview, [ADDRESS_1237105] dose of study drug. 

Protocol VX1 8-150-104, Version  2.0 Page 41 of 51 
Vertex Pharmaceuticals Incorporated   All subjects will be queried, using nonleading questions, about the occurrence of AEs at each 
study visit. When possible, a constellation of signs and/or symptoms will be identified as 
[ADDRESS_1237106]’s source documents. The following data will be documented for each AE:  
• Description of the event 
• Classification of “serious” or “nonserious” 
• Date of first occurrence and date of resolution (if applicable) 
• Severity  
• Causal relationship to study drug(s)  
• Actio n taken  
• Outcome  
• Concomitant medication or other treatment given  
[IP_ADDRESS]  Adverse Event Severity  
The investigator will determine and record the severity of all serious and nonserious AEs. The guidance available at the following website will be consulted: Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, Cancer Therapy Evaluation Program, http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  (Accessed 
November 2017). AEs of CTCAE Grades  4 and 5 will be documented as “life- threatening.” The 
severity of an AE that does not appear in the CTCAE will be determined according to the definitions in Table 13-1.  
Table 13-1 Grading of AE Severity  
Classification  Definition  
Mild (Grade  1) Mild level of discomfort and does not interfere with regular activities  
Moderate (Grade  2) Moderate level of discomfort and significantly interferes with regular activities  
Severe (Grade  3) Significant level of discomfort and prevents regular activities  
Life-threatening (Grade  4) Any adverse drug event that places the subject, in the view of the investigator, at 
immediate risk of death  
 
[IP_ADDRESS]  Adverse Event  Causality  
Every effort will be made by [CONTACT_63398], if any, to the study drug(s). Causality will be classified using the categories in  Table 13-2. 

Protocol VX1 8-150-104, Version  2.[ADDRESS_1237107] been ruled out, 
and/or the event reappeared on re -exposure to the investigational study drug.  
Possibly related  Ther e is an association between the event and the administration of the 
investigational study drug and there is a plausible mechanism for the event to be 
related to investigational study drug, but there may also be alternative etiology, such 
as characteristics  of the subject’s clinical status or underlying disease.  
Unlikely related  The event is unlikely to be related to the investigational study drug and likely to be 
related to factors other than investigational study drug.  
Not related  The event is related to an etiology other than the investigational study drug (the 
alternative etiology will be documented in the subject’s medical record).  
 
[IP_ADDRESS]  Study Drug Action Taken  
The investigator will classify the study drug action taken with regard to the AE. The action taken 
will be classified according to the categories in  Table 13-3.  
Table 13-[ADDRESS_1237108] to an AE 
Classification  Definition  
Dose not changed  Study drug dose not changed in response to an AE  
Dose reduced  Study drug dose reduced in response to an AE  
Drug interrupted  Study drug administration interrupted in response to an AE  
Drug withdrawn  Study drug administration permanently discontinued in response to an AE  
Not applicable  Action taken regarding study drug administration does not apply.  
“Not applicable” will be used in circumstances such as when the investigational 
treatment had been completed before the AE began and no opportunity to decide 
whether to continue, interrupt, or withdraw treatment is possible.  
 
[IP_ADDRESS]  Adverse Event Outcome 
An AE will be followed until the investigator has determined and provided the final outcome. 
The outcome will be classified according to the categories in  Table 13-4.  

Protocol VX1 8-150-104, Version  2.0 Page 43 of 51 
Vertex Pharmaceuticals Incorporated   Table 13-4 Classifications for Outcome of an AE 
Classification  Definition  
Recovered/resolved  Resolution of an AE with no residual signs or sy mptoms  
Recovered/resolved with 
sequelae  Resolution of an AE with residual signs or symptoms  
Not recovered/not 
resolved (continuing)  Either incomplete improvement or no improvement of an AE, such that it remains 
ongoing  
Fatal  Outcome of an AE is death. “Fatal” will be used when death is at least possibly 
related to the AE.  
Unknown  Outcome of an AE is not known (e.g.,  a subject lost to followup)  
 
[IP_ADDRESS]  Treatment Given  
The investigator ensures adequate medical care is provided to subjects for any AEs, including 
clinically significant laboratory values related to study drug. In addition, the investigator will describe whether any treatment was given for the AE. “Yes” is used if any treatment was given in response to an AE, and may include treatments such as other medications, surgery, or physical therapy. “No” indicates the absence of any kind of treatment for an AE.  
13.1.2  Serious Adverse Events 
[IP_ADDRESS]  Definition of a Serious Adverse Event  
An SAE is any AE that meets any of the following outcomes:  
• Fatal (death, regard less of cause, that occurs during participation in the study or occurs after 
participation and is suspected of being a delayed toxicity due to administration of the study drug) 
• Life-threatening, such that the subject was at immediate risk of death from the  reaction as it 
occurred  
• Inpatient hospi[INVESTIGATOR_318] 
• Persistent or significant disability/incapacity (disability is defined as a substantial disruption 
of a person’s ability to conduct normal life functions) 
• Congenital anomaly or birth defect  
• Important medical event that, based upon appropriate medical judgment, may jeopardize the subject or may require medical or surgical intervention to prevent 1 of the outcomes listed 
above (e.g., an allergic bronchospasm requiring intensive treatment in an emergency room or at home)  
If a subject has a hospi[INVESTIGATOR_29918] (e.g., surgery) for an event or condition that occurred before the subject signed the ICF, and the hospi[INVESTIGATOR_139355], the hospi[INVESTIGATOR_168788], unless an AE caused the hospi[INVESTIGATOR_139357]. In addition, hospi[INVESTIGATOR_94253] (e.g.,  social hospi[INVESTIGATOR_8933]) will not be 
considered to indicate an SAE. 

Protocol VX1 8-150-104, Version  2.0 Page 44 of 51 
Vertex Pharmaceuticals Incorporated   Clarification will be made between the terms “serious” and “severe” because they are not 
synonymous. The term “severe” is ofte n used to describe the intensity (severity) of a specific 
event, as in mild, moderate, or severe myocardial infarction. The event itself, however, may be of relatively minor medical significance, such as a severe headache. This is not the same as “serious ,” which is based on subject/event outcome or action described above and  is usually 
associated with events that pose a threat to a subject’s life or functioning. Seriousness, not severity, serves as a guide for defining expedited regulatory reporting obligations.  
[IP_ADDRESS]  Reporting and Documentation of Serious Adverse Events  
All SAEs that occur after obtaining informed consent and assent (where applicable) through the 
Safety Follow -up Phone Interview, regardless of causality, will be reported by [CONTACT_168800] 24 hours of identification . In addition, all SAEs that occur after the Safety 
Follow-up Phone Interview and are considered related to study drug(s) will be reported to Vertex GPS within 24  hours of identification .  
For SAEs that occur after obtaining informed consent and assent (where applicable) through the Safety Follow -up Phone Interview , the SAE Form will be completed for new/initial events as 
well as to report follow -up information on previously reported events. Investigators are asked to 
report follow-up information as soon as it becomes available to ensure timely reporting to health authorities.  
Please send completed SAE Forms to Vertex GPS via:  
Email:  (preferred choice)  
Fax:   
For questions, contact [CONTACT_756]:  
SAEs that occur after the Safety Follow-up Phone Interview and are considered related to study 
drug(s) will be recorded on the Vertex Organized Safety Information Collection Form (hereafter 
referred to as the “SAE Form”) using a recognized medical term or diagnosis that accurately reflects the event. SAEs will be assessed by [CONTACT_94316](s) and possible etiologies. On the SAE Form, relationship to study dru g(s) will be 
assessed only as related (includes possibly related) or not related (includes unlikely related), and severity assessment will not be required. For the purposes of study analysis, if the event has not resolved at the end of the study reporting period, it will be documented as ongoing. For purposes of regulatory safety monitoring, the investigator is required to follow the event to resolution and report the outcome to Vertex using the SAE Form. 
[IP_ADDRESS]  Expedited Reporting and Investigator Safety Letters  
Vertex, as study sponsor, is responsible for reporting suspected, unexpected, serious adverse 
reactions (S[LOCATION_003]Rs) involving the study drug(s) to all regulatory authorities, IECs, and participating investigators in accordance with ICH Guidelines and/or local regulatory requirements, as applicable. In addition, Vertex, or authorized designee, will be responsible for the submission of safety letters to central IECs.  
It is the responsibility of the investigator or designee to promptly notify the local IRB/IEC o f all 
unexpected serious adverse drug reactions involving risk to human subjects. 

Protocol VX1 8-150-104, Version  2.0 Page 45 of 51 
Vertex Pharmaceuticals Incorporated   13.2 Administrative Requirements  
13.2.1  Ethical Considerations  
The study will be conducted in accordance with the current ICH GCP Guidelines, which are 
consistent with the ethical principles founded in the Declaration of Helsinki, and in accordance with local applicable laws and regulations. The IRB/IEC will review all appropriate study documentation to safeguard the rights, safety, and well-being of the subjects. The study will be conducted only at sites where IRB/IEC approval has been obtained. The protocol, Investigator’s Brochure, sample ICF, advertisements (if applicable), written information given to the subjects (including diary cards), safety updates, annual progress reports, and any revisions to these documents will be provided to the IRB/IEC by [CONTACT_155432], as allowable by [CONTACT_94318]. 
13.2.[ADDRESS_1237109] before study participation. The method of obtaining and documenting the informed consent and assent (if applicable) and the contents of the consent will comply with ICH GCP and all applicable laws and regulations and will be subject to approval by [CONTACT_139411]. 
13.2.[ADDRESS_1237110] the safety of the subjects, the scope of t he investigation, 
or the scientific quality of the study (i.e.,  efficacy assessments) will require IRB/IEC notification 
before implementation, except where the modification is necessary to eliminate an apparent immediate hazard to human subjects. Vertex wi ll submit all protocol modifications to the 
required regulatory authorities. 
When circumstances require an immediate departure from procedures set forth in the protocol, 
the investigator will contact [CONTACT_139412]. If possi ble, contact 
[CONTACT_94321]. Any departures from the protocol will be fully documented in the source documentation and in a protocol deviation log.  
13.2.4  Access to Records  
The investigator will make the office and/or hospi [INVESTIGATOR_168790]. The records will also be available for direct inspection, verification, and copying, as required by [CONTACT_774], by [CONTACT_775] 
(FDA and others). The investigator will comply with applicable privacy and security laws for use and disclosure of information related to the research set forth in this protocol.  
13.2.[ADDRESS_1237111] names linked to such numbers will be limited to the site and the study physician and will not be disclosed to Vertex. As required by [CONTACT_94323], the investi gator will allow Vertex and/or its representatives access to all pertinent 
medical records to allow for the verification of data gathered in the CRFs/SAE Forms and the 

Protocol VX1 8-150-104, Version  2.0 Page 46 of 51 
Vertex Pharmaceuticals Incorporated   review of the data collection process. The FDA and regulatory authorities in other jurisdictions, 
including the IRB/IEC, may also request access to all study records, including source documentation, for inspection. 
For sites participating in the US, and in accordance with the Health Insurance Portability and 
Accountability Act (HIPAA) and ass ociated regulations, an executed HIPAA authorization will 
be obtained by [CONTACT_94324] (or the legal representative of the subject) before research activities may begin. Each HIPAA authorization will comply with all HIPAA requirements including authorization allowing the site access to and use of the subject’s personally identifiable health information, authorization for the site to disclose such information to Vertex, the FDA, and other parties requiring access under the protocol, and statements as to the purpose for which such information may be used and for how long. 
13.2.[ADDRESS_1237112] Retention  
The investigator will maintain all study records according to ICH  GCP Guidelines and/or 
applicable local regulatory requirement(s), whichever is longest, as desc ribed in the Clinical 
Trial Agreement. If the investigator withdraws from the responsibility of keepi[INVESTIGATOR_94255], custody will be transferred to a person willing to accept the responsibility and Vertex will be notified.  
13.2.7  Study Termination 
At any time, Vertex may terminate this study in its entirety or may terminate this study at any particular site. In addition, for reasonable cause, either the investigators or their IRBs/IECs may terminate the study at their center.  
Conditions that may lead to reasonable cause and warrant termination include, but are not limited 
to: 
• Subject or investigator noncompliance 
• Unsatisfactory subject enrollment 
• Lack of adherence to protocol procedures 
• Lack of evaluable and/or complete data  
• Potentially unacceptab le risk to study subjects  
• Decision to modify drug development plan 
• Decision by [CONTACT_155434].  
13.2.[ADDRESS_1237113] scheduled visit (or contact) of the last subject.  
13.[ADDRESS_1237114] will be entered into a CRF by [CONTACT_94326] a secure, validated, web -based electronic data capture (EDC) application. Vertex will have read -only 
access to site- entered clinical data in the EDC application.  
Instances of missing, discrepant, or uninterpretable data will be queried with the investigator for resolution. Any changes to study data will be made to the CRF and documented in an audit trail, which will be maintained within the clinical database.  
13.4 Monitoring  
Monitoring and auditing procedures developed or approved by [CONTACT_884256]. On-site checking of the CRFs/SAE Forms for completeness and clarity, cross -checking with source docume nts, and clarification of administrative matters will be 
performed.  
The study will be monitored by [CONTACT_139411]. Monitoring will be done by [CONTACT_782] a representative of Vertex or designee (study site monitor), who will review the CRFs /SAE Forms and source documents. The study site monitor will ensure that the 
investigation is conducted according to the protocol design and regulatory requirements. 
13.[ADDRESS_1237115]. It is the investigator’s responsibil ity to 
ensure the accuracy, completeness, clarity, and timeliness of the data reported in the subject’s 
CRF. Source documentation supporting the CRF data will indicate the subject’s participation in the study and will document the dates and details of study procedures, AEs, other observations, and subject status. 
The investigator, or designated representative, will complete the CRF as soon as possible after 
information is collected.  
The audit trail entry will show the user’s identification information and the date and time of any 
correction. The investigator will provide formal approval of all the information in the CRFs, including any changes made to them, to endorse the final submitted data for the subjects for whom the investigator is responsible.  
Vertex will retain the CRF data  and corresponding audit trails. A copy of the final archival CRF 
in the form of a compact disc (CD) or other electronic media will be placed in the investigator’s 
study file.  
13.6 Publications and Clinical Study Report  

Protocol VX1 8-150-104, Version  2.0 Page 48 of 51 
Vertex Pharmaceuticals Incorporated   13.6.2  C
linical Study Report  
A CSR, written in accordance with the ICH E3 Guideline, will be submitted in accordance with 
local regulations. 

Protocol VX18 -150-104, Version  2.0 Page 49 of 51 
Vertex Pharmaceuticals Incorporated   14 REFERENCES  
1 Petersen KL, Rowbotham MC. Will ion-channel blockers be useful for management of 
nonneuropathic pain? The Journal of Pain. 2000;1(3):26-34. 
2 Centers for Disease Control and Prevention. 2017. Opi[INVESTIGATOR_884244]: 
https://www.cdc.gov/drugoverdose/ . Accessed [ADDRESS_1237116] 2018. 
3 European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 
2016: Trends and Developments. Lisbon, Portugal: 2016. 
4 Rush AM, Cummins TR. Pa inful research: identification of a small-molecule inhibitor 
that selectively targets Nav1.8 sodium channels. Molecular Interventions. 2007;7(4):192-
5. 
5 England S. Voltage-gated sodium channels: the search for subtype- selective analgesics. 
Expert Opi[INVESTIGATOR_194444]. 2008;17(12):1849-64. 
6 Krafte D, Bannon A. Sodium channels and nociception: recent concepts and therapeutic 
opportunities. Current Opi[INVESTIGATOR_283432]. 2008;8(1):50-6. 
7 Huang J, Yang Y, Zhao P, Gerrits MM, Hoeijmakers JGJ, Be kelaar K, et al. Small -fiber 
neuropathy Nav1.8 mutation shifts activation to hyperpolarized potentials and increases excitability of dorsal root ganglion neurons. Journal of Neuroscience. 2013;33(35):[ZIP_CODE]-97. 
8 Faber CG, Lauria G, Merkies ISJ, Cheng X, Han C, Ahn HS, et al. Gain-of-function 
Nav1.8 mutations in painful neuropathy. Proceedings of the National Academy of Sciences. 2012;109(47):[ZIP_CODE]-49. 
9 Han C, Vasylyev D, Macala LJ, Gerrits MM, Hoeijmakers JGJ, Bekelaar KJ, et al. The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. Journal of Neurology, Neurosurgery & Psychiatry. 2013;85(5):499-505. 
10 Akopi[INVESTIGATOR_306007], Sivilotti L, Wood JN. A tetrodotoxin- resistant voltage -gated sodium 
channel expressed by [CONTACT_306032]. Nature. 1996;379(6562):257-62. 
11 Vertex Pharmaceuticals Incorporated. VX -150 Investigator’s Brochure.  
12 [LOCATION_002] Department of Health and Human Services. Food and Drug Administration. 
Center for Drug Evaluation and Research . Draft guidance for industry: analgesic 
indications: developi[INVESTIGATOR_306008]. Rockville, MD: February 2014. 
[ADDRESS_1237117], Ardia A, Pallotta T. A controlled comparative study of ibuprofen arginate 
versus conventional ibuprofen in the treatment of postoperative dental pain. J Clin Pharmacol. 2002;42(8):904-11. 
14 Cooper SA, Desjardins PJ, Turk DC, Dworkin RH, Katz NP, Kehlet H, et al. Research 
design considerations for single- dose analgesic clinical trials in acute pain: IMMPACT 
recommendations. Pain. 2016;157(2):288-301. 
15 Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461-4. 
16 International Committee of Medical Journal Editors (ICMJE). 2017. Recommendations 
for conduct, reporting, editing, and publication of scholarly work in medical journals. Available at: http://www.icmje.org/recommendations /. Accessed 09 April 2018. 
 

Protocol VX18-150-104, Version 2.0 Page 50 of 51 
15 PROTOCOL SIGNATURE [CONTACT_118585] 
15.1 Sponsor Signature [CONTACT_168805]#: VX18-150-104 I Version#: 2.0 I Version Date: 26 September 2018 
Study Title: A Phase 2B Randomized, Double-blind, Placebo-controlled, Dose-ranging, 
Parallel-design Study of the Efficacy and Safety ofVX-150 for Acute Pain Following 
Bunionectomy 
Vertex Pharmaceuticals Incorporated  

Protocol VX18 -150-104, Version  2.0 Page 51 of 51 
Vertex Pharmaceuticals Incorporated   15.2 Investigator Signature [CONTACT_94333] #:  VX18‑150‑104 Version #:  2.0 Version Date:  26 September  2018  
Study Title:  A Phase 2B Randomized, Double -blind, Placebo -controlled, Dose -ranging, 
Parallel -design Study of the Efficacy and Safety of VX-[ADDRESS_1237118] read Protocol VX18‑150‑104, Version 2.0, and agree to conduct the study according to 
its terms. I understand that all information concerning VX-150 and this protocol supplied to me 
by [CONTACT_139369] (Vertex) is confidential.  
 
 
Printed Name    
[CONTACT_155436]  
   
